Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with lowor low-normal testosterone levels: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 314, Issue 6, 2015, Pages 570-581

  Basaria, Shehzad ^a   Harman, S Mitchell ^b,c   Travison, Thomas G ^a,j   Hodis, Howard ^d   Tsitouras, Panayiotis ^b,e   Budoff, Matthew ^f   Pencina, Karol M ^a   Vita, Joseph ^g   Dzekov, Connie ^h   Mazer, Norman A ^g,i   Coviello, Andrea D ⁱ   Knapp, Philip E ⁱ   Hally, Kathleen ^a   Pinjic, Emma ^a   Yan, Mingzhu ^d   Storer, Thomas W ^a   Bhasin, Shalender ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Kronos Longevity Research Institute   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j Hebrew Senior Life   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL; CALCIUM;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HEMATOLOGIC DISEASE; HUMAN; INTIMACY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; ORGASM; PATIENT COMPLIANCE; PENIS ERECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SEXUAL SATISFACTION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; CORONARY BLOOD VESSEL; DEFICIENCY; DISEASE COURSE; HEALTH STATUS; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; OBESITY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

AGED; ATHEROSCLEROSIS; CALCIUM; CAROTID INTIMA-MEDIA THICKNESS; CORONARY VESSELS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HEALTH STATUS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; QUALITY OF LIFE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84939137793     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.8881     Document Type: Article

References (43)

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-1466.
2. Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
3. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
4. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatalmyocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.
5. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
6. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058.
7. Bhasin S, Jasjua GK, Pencina M, et al. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart study. Diabetes Care. 2011;34(11): 2464-2470.
8. Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab. 2003;88(11):5076-5086.
9. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10): 3007-3019.
10. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation. 1988;78(3):539-545.
11. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004; 109(17):2074-2079.
12. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001;98(6):3589-3593.
13. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128 (4):262-269.
14. Hodis HN, Mack WJ, Lobo RA, et al; Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135 (11):939-953.
15. Budoff MJ, Young R, Lopez VA, et al. Progression of coronary calcium and incident coronary heart disease events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61 (12):1231-1239.
16. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249-260.
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6):822-830.
18. Paige NM, Hays RD, Litwin MS, Rajfer J, Shapiro MF. Improvement in emotional well-being and relationships of users of sildenafil. J Urol. 2001;166 (5):1774-1778.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: Conceptual framework and item selection. Med Care. 1992;30 (6):473-483.
20. Salameh WA, Redor-Goldman MM, Clarke NJ, Reitz RE, Caulfield MP. Validation of a total testosterone assay using high-turbulence liquid chromatography tandem mass spectrometry: total and free testosterone reference ranges. Steroids. 2010;75(2):169-175.
21. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. 2012;307(9): 931-939.
22. Mazer NA. A novel spreadsheetmethod for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. Steroids. 2009;74 (6):512-519.
23. Van Buuren S, Groothuis-Oudshoorn K. Multivariate Imputation by Chained Equations: MICE V1.0 User's Manual. Leiden, the Netherlands: TNO Quality of Life; 2000.
24. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88(1):20-28.
25. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med. 1996;124(6):548-556.
26. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA; Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404.
27. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of ameta-analysis. J Urol. 2000;164(2):371-375.
28. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of ameta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381-394.
29. Buena F, Swerdloff RS, Steiner BS, et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril. 1993;59(5):1118-1123.
30. Grey PB, Singh AB, Woodhouse L, et al. Dose-dependent effects of testosterone on sexual function in older men. J Clin Endocrinol Metab. 2005;90:3838-3846.
31. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369 (11):1011-1022.
32. Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014;11(3):362-375.
33. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647-2653.
34. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299(1):39-52.
35. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647-1659.
36. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90(3): 1502-1510.
37. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639-650.
38. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296 (19):2351-2361.
39. Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837.
40. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321-333.
41. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med. 2013;10(5):1401-1409.
42. Jasuja GK, Bhasin S, Reisman JI, Rose AJ. Wide variations in the use of testosterone therapy among VA facilities. Am J Pharm Benefits. 2013;5(5):e122-e128.
43. Budoff MJ, Lane KL, Bakhsheshi H, et al. Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol. 2000;86(1):8-11.